You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES
  1. PLASMA & BIOTHERAPIES - 07-04-2021

    Rh&Life, first subject included in the study

    Two hundred pregnant women to be enrolled over five countries

    read more 
  2. PLASMA & BIOTHERAPIES - 02-04-2021

    KIDCARES10, first patient enrolled in pediatric PI study

    Thirty patients aged 2 to 17 years old to be enrolled over five European countries

    read more 
  3. PLASMA & BIOTHERAPIES - 01-04-2021

    Updates on anti-COVID treatment developed by Kamada and Kedrion

    Top-line results announced from the phase 1/2 clinical trial in Israel

    read more 
  4. PLASMA & BIOTHERAPIES - 11-01-2021

    CARES10 clinical trial: last patient treated in the USA

    Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients

    read more 

Pages

For more information please contact: [email protected]